Previous 10 | Next 10 |
ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q3 Non-GAAP EPS of $0.64 beats by $0.09 . Revenue of $83.8M (+61.0% Y/Y) beats by $5.44M . Adjusted non-GAAP EBITDA of $19.6M. Reiterates total Company net revenue guidance of $295 million to $315 million ...
Third Quarter 2022 Results: -- Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55) -- -- Adjusted non-GAAP EBITDA of $19.6 million and adjusted non-GAAP diluted earnings per share...
ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q3 earnings results on Wednesday, November 9th, before market open. The consensus EPS Estimate is $0.55 (-45.5% Y/Y) and the consensus Revenue Estimate is $78.36M (+50.5% Y/Y). Over the last 2 years, ANIP ...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, prior to market open. Nikhil Lalwani, President and Chief Executive Of...
The following slide deck was published by ANI Pharmaceuticals, Inc. in conjunction with this event. For further details see: ANI Pharmaceuticals (ANIP) presents at H.C. Wainwright 24th Annual Global Investment Conference - Slideshow
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership ex...
ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 24 th Annual Global Investment Conference as fo...
The U.S. Food and Drug Administration (FDA) approved ANI Pharmaceuticals' ( NASDAQ: ANIP ) generic dexamethasone tablets USP 1.5mg, 4mg and 6mg. The company's dexamethasone tablets are the generic version of reference drug Decadron. Dexamethasone is a type of ...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Dexamethasone Tablets USP 1.5mg, 4mg and 6mg. ANI’s Dexamethasone Table...
ANI Pharmaceuticals, Inc. (ANIP) Q2 2022 Earnings Conference Call August 8, 2022 08:00 ET Company Participants Lisa Wilson - Investor Relations Nikhil Lalwani - President & Chief Executive Officer Steve Carey - Chief Financial Officer, Senior Vice President o...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....
PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year ® 2024 New Jersey Award winner. Entr...
2024-06-24 08:08:29 ET Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sc...